Objective: To evaluate the impact of Levodopa/Entacapone/Carbidopa Gel (LECIG) therapy on Parkinson’s disease (PD) patients, their caregivers, and clinicians over six months.

Background: Advanced PD treatment aims to improve not only motor symptoms but also overall patient quality of life and caregiver burden. LECIG is a novel continuous dopaminergic therapy that may provide benefits beyond traditional oral levodopa therapy. However, its multidimensional impact has not been thoroughly assessed.

Method: We conducted a prospective observational study assessing LECIG efficacy in PD patients over six months. Evaluations included: Caregiver burden: Parkinson’s Disease Caregiver Burden Questionnaire (PDCBQ-A, PDCBQ-B), Patient-reported outcomes: Parkinson’s Disease Questionnaire-8 (PDQ-8), Patients’ Global Impression of Change (PGIC), Clinician assessment: Clinical Global Impression – Global Improvement (CGI-I) scale.

Results: We collected complete data from 21 patients. LECIG treatment significantly improved the PDQ-8 score (11.06 ± 6.27 vs. 8.71 ± 5.34, p = 0.004, d = 0.708). According to PGIC, 73.5% of patients improved, 19.8% worsened, and 6.7% remained unchanged. Clinician-reported CGI-I outcomes indicated that 68.4% of patients were rated as “very much” or “much improved,” 31.6% as “minimally improved” or “unchanged,” and 0% worsened. The PDCBQ-A score significantly improved after six months of LECIG treatment (114.42 ± 8.74 vs. 89.67 ± 8.13, p < 0.001, d = 2.543).

Conclusion: LECIG therapy significantly reduces caregiver burden and improves patient-reported quality of life in PD. Clinician assessments corroborate these benefits, with no reported worsening. These findings highlight the importance of continuous dopaminergic stimulation in managing advanced PD.

« Back to 2025 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/multidimensional-assessment-of-levodopa-carbidopa-entacapone-gel-lecig-therapy-in-parkinsons-disease-perspectives-of-patients-clinicians-and-caregivers/